Omeros: Why The Novo Nordisk Deal Is More Important Than FDA Approval (Rating Upgrade) [Seeking Alpha]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Seeking Alpha
YARTEMLEA's U.S. peak annual sales are estimated at no more than $250 million, given the niche, fragmented TA-TMA market and entrenched off-label competition. The Novo Nordisk partnership delivers $340M upfront/near-term, removes dilution risk, validates the pipeline, but limits future upside from zaltenibart. I upgrade OMER to Hold; current valuation fairly reflects YARTEMLEA, zaltenibart, and pipeline optionality, with profitability unlikely from YARTEMLEA alone. We Are/DigitalVision via Getty Images Introduction Omeros ( OMER ) has undergone quite a transformation since I last wrote about it in August 2023. My Sell rating then hinged on poor prospects for narsoplimab, its lead MASP-2 inhibitor, in IgA nephropathy (IgAN), as This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and i
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk (NVO) Gets 9% Boost from Wegovy Pill OK [Yahoo! Finance]Yahoo! Finance
- The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA. [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk just pulled off something nobody saw coming [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk: Oral Weight-Loss To The Rescue [Seeking Alpha]Seeking Alpha
- 3 Drug Stocks to Buy at a Discount [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 12/23/25 - Form 6-K
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- NVO's page on the SEC website